Tailoring viral vector transgene optimization for enhanced efficacy

Dr. Brown received his Doctorate in Molecular and Systems Pharmacology from Emory University, where he developed the bioengineered transgene cassette for a second generation AAV gene therapy entering clinical trials through a licensing agreement with ASC Therapeutics. He joined Expression Therapeutics in 2020 to help develop and implement a suite of platform technologies for research and manufacturing.

Dr. Brown’s work at Expression Therapeutics focuses on developing novel gene transfer systems, therapeutic proteins, and cell therapies with a special focus on cancer and bleeding disorders. The company uses automated, “big data” driven bioinformatics and traditional molecular-driven studies to create therapeutic platforms that provide both scalability and indication-specific customization. They have used these tools internally to design proprietary platforms for novel gamma delta T cell, lentiviral, AAV, and mRNA-based therapies across multiple indications. By integrating these tools in its GMP-ready CDMO pipeline Expression Therapeutics is able to offer the efficiency of “off the shelf” vector components combined with AI-enabled transgene optimization, which combine to allow rapid development and manufacture of the next generation of biotherapies.